Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Palpitations, Pyrexia, Tachycardia
Clinical narrative: chest pain; shortness of breath; heart palpitations; high fever; Tachycardia; This is a spontaneous report received from a contactable reporter(s) (Other HCP/Nurse) via . The reporter is the patient.  A 32-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 16Nov2021 09:30 (Batch/Lot number: unknown) at the age of 32 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing); "ADHD" (unspecified if ongoing); "Known allergies: Opiates" (unspecified if ongoing), notes: Known allergies: Opiates. Concomitant medication(s) included: TYLENOL; IBUPROFEN. Past drug history included: Augmentin, reaction(s): "Known allergies: Augmentin"; Cipro, reaction(s): "Known allergies: Cipro"; Compazine, reaction(s): "Known allergies: Compazine". Vaccination history included: Bnt162b2 (Dose: 1, Location: Left arm), administration date: 26Oct2021, when the patient was 32 years old, for Covid-19 Immunization. The patient had not received any other vaccines in four weeks, was not diagnosed with COVID prior to vaccination and was not tested for COVID-19 since vaccination. The following information was reported: TACHYCARDIA (medically significant) with onset 16Nov2021, outcome "not recovered", described as "Tachycardia"; CHEST PAIN (medically significant) with onset 16Nov2021 21:30, outcome "not recovered", described as "chest pain"; DYSPNOEA (medically significant) with onset 16Nov2021 21:30, outcome "not recovered", described as "shortness of breath"; PALPITATIONS (medically significant) with onset 16Nov2021 21:30, outcome "not recovered", described as "heart palpitations"; PYREXIA (medically significant) with onset 16Nov2021 21:30, outcome "not recovered", described as "high fever". The events "tachycardia", "chest pain", "shortness of breath", "heart palpitations" and "high fever" were evaluated at the emergency room visit. The patient reported 12 hours after receiving the second Pfizer dose, she began to have chest pain, shortness of breath, high fever, and heart palpitations. She went to the emergency department to be seen after chest pain and tachycardia did not subside. Tachycardia continued along with shortness of breath. The patient underwent the following laboratory tests and procedures: chest x-ray: unknown results; electrocardiogram: unknown results; laboratory test: unknown results. Therapeutic measures were taken as a result of tachycardia, chest pain, dyspnoea, palpitations, pyrexia. The patient was administered fluids intravenously. The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Based on the current information available and considering plausible drug-event temporal association a possible contributory role of the suspect BNT162B2 for the reported events of Tachycardia, Chest pain, Dyspnoea, Palpitations and Pyrexia cannot be completely excluded. The case will be reassessed further upon receipt of additional information. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.